B regulatory cells in allergy

Ma, Siyuan; Satitsuksanoa, Pattraporn; Jansen, Kirstin; Cevhertas, Lacin; Veen, Willem van de; Akdiş, Mübeccel

doi:10.1111/imr.12937

Cited by 33 publications

(22 citation statements)

References 182 publications

(242 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Breg cells are immunosuppressive B cells that have been described in both mice and humans and which have been receiving increasing attention during the last two decades 99 . Certain subpopulations of plasma cells have been recently included under the umbrella of Breg cells 100,101 …”

Section: Immunological Mechanisms In Dhrsmentioning

confidence: 99%

Advances and highlights in T and B cell responses to drug antigens

Fernandez

Ariza

Fernández

et al. 2021

Allergy

View full text Add to dashboard Cite

The immunological mechanisms involved in drug hypersensitivity reactions (DHRs) are complex, and despite important advances, multiple aspects remain poorly understood. These not fully known aspects are mainly related to the factors that drive towards either a tolerant or a hypersensitivity response and specifically regarding the role of B and T cells. In this review, we focus on recent findings on this knowledge area within the last 2 years. We highlight new evidences of covalent and non‐covalent interactions of drug antigen with proteins, as well as the very first characterization of naturally processed flucloxacillin‐haptenated human leukocyte antigen (HLA) ligands. Moreover, we have analysed new insights into the identification of risk factors associated with the development of DHRs, such as the role of oxidative metabolism of drugs in the activation of the immune system and the discovery of new associations between DHRs and HLA variants. Finally, evidence of IgG‐mediated anaphylaxis in humans and the involvement of specific subpopulations of effector cells associated with different clinical entities are also topics explored in this review. All these recent findings are relevant for the underlying pathology mechanisms and advance the field towards a more precise diagnosis, management and treatment approach for DHRs.

show abstract

Section: Immunological Mechanisms In Dhrsmentioning

confidence: 99%

Advances and highlights in T and B cell responses to drug antigens

Fernandez

Ariza

Fernández

et al. 2021

Allergy

View full text Add to dashboard Cite

show abstract

“…They participate to the control of tolerance and restrain the development of improper immune responses through direct cellto-cell contact with targeted cells and/or through the production of cytokines such as IL-10, TGFb or IL-35 (Table 1). Hence, dysfunctional Bregs have been suspected to contribute to the expansion of aberrant autoimmunity (40)(41)(42), of uncontrolled inflammatory responses (43), of inappropriate tumor development (44), as well as graft rejection (45) or allergic reactions (46). Notwithstanding their important contributions in the control of various immune-mediated responses, little is known about the intracellular pathways leading to their differentiation and governing the acquisition of their functions as well as the incidence of metabolic programs (47,48).…”

Section: The Intra-signalling Pathways In the Regulatory Functionsmentioning

confidence: 99%

Metabolic Program of Regulatory B Lymphocytes and Influence in the Control of Malignant and Autoimmune Situations

et al. 2021

View full text Add to dashboard Cite

Metabolic pathways have been studied for a while in eukaryotic cells. During glycolysis, glucose enters into the cells through the Glut1 transporter to be phosphorylated and metabolized generating ATP molecules. Immune cells can use additional pathways to adapt their energetic needs. The pentose phosphate pathway, the glutaminolysis, the fatty acid oxidation and the oxidative phosphorylation generate additional metabolites to respond to the physiological requirements. Specifically, in B lymphocytes, these pathways are activated to meet energetic demands in relation to their maturation status and their functional orientation (tolerance, effector or regulatory activities). These metabolic programs are differentially involved depending on the receptors and the co-activation molecules stimulated. Their induction may also vary according to the influence of the microenvironment, i.e. the presence of T cells, cytokines … promoting the expression of particular transcription factors that direct the energetic program and modulate the number of ATP molecule produced. The current review provides recent advances showing the underestimated influence of the metabolic pathways in the control of the B cell physiology, with a particular focus on the regulatory B cells, but also in the oncogenic and autoimmune evolution of the B cells.

show abstract

“…The following lung function parameters were recorded according to ATS/ERS standards using a Jaeger body plethysmograph with corrections for temperature and barometric pressure: forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and FEV1/ activity mediated by IL-10, IL-35 and TGF-beta release, inducing activation of Tregs [12][13][14][15]. Types of human Breg cells have different surface markers characterising different subsets, such as CD27 + CD24 hi cells, CD24 hi CD38 hi immature/transitional B cells and CD5 + CD1d hi [16].…”

Section: Lung Function Testsmentioning

confidence: 99%

Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy

et al. 2021

View full text Add to dashboard Cite

Background Severe allergic asthma (SAA) is based on type 2 (T2-high) immune responses to allergens promoting type 2 T helper (Th2) cell cytokine responses and production of IgE antibodies. Omalizumab was the first biological drug licensed for clinical use in the management of IgE-mediated SAA. Despite emerging evidence supporting the prominent role of follicular T cells (Tfh), Breg and Treg subsets, in the development and progression of SAA, no data are available on the impact of omalizumab therapy. Methods Ten SAA patients monitored at the Respiratory Diseases Unit of Siena University Hospital and ten healthy sex-and age-matched controls were enrolled in the study. Clinical and functional parameters were collected at baseline (T0) and after 6 months of therapy (T6). Cellular population analysis was determined through multicolour flow cytometry. Results SAA patients showed higher percentages of Th17.1, Tfh and Tfh2 while CD24 hi CD27 hi Breg cell, Treg and Tfr percentages were significantly lower than in controls. Higher percentages of Tfh2 in patients with nasal polyps than in those without and in controls were observed. At T6, significant decreases in Tfh and Tfh2 compared with T0 were observed. A slightly significant increase in Teffs was reported at T6 compared to T0. ΔIgE levels in serum were correlated with ΔCD19 + CD24 + CD27 + Breg cell percentages (r = − 0.86, p = 0.0022). Conclusions Our data explored the changes in Tfh cells, Tregs and Bregs in severe asthma. The restoration of immunological imbalance in SAA patients after omalizumab is certainly intriguing and represents a glimpse into the comprehension of immunological effects of treatment.L. Bergantini and M. d'Alessandro contributed equally to the study.

show abstract

B regulatory cells in allergy

Cited by 33 publications

References 182 publications

Advances and highlights in T and B cell responses to drug antigens

Advances and highlights in T and B cell responses to drug antigens

Metabolic Program of Regulatory B Lymphocytes and Influence in the Control of Malignant and Autoimmune Situations

Follicular T Helper and Breg Cell Balance in Severe Allergic Asthma Before and After Omalizumab Therapy

Contact Info

Product

Resources

About